Crinetics Pharmaceuticals (CRNX) Corporate presentation summary

Strategic vision and mission

• Aims to be the world's leading endocrine company, pioneering new therapeutics for better disease control and improved patient lives.

• Focuses on transforming endocrine disease treatment from discovery to commercialization, with a robust pipeline of over 10 wholly owned assets and IP protection into the 2040s.

• Vision for 2030 includes two marketed products, four approved indications, and seven or more clinical pipeline candidates.

Product pipeline and clinical progress

• PALSONIFY (paltusotine) is approved for acromegaly in the US, with strong launch metrics and expanding prescriber base.

• Paltusotine is in Phase 3 for carcinoid syndrome, showing significant reductions in flushing and bowel movement frequency in Phase 2.

• Atumelnant, an oral ACTH antagonist, is in Phase 3 for congenital adrenal hyperplasia (CAH) and being developed for ACTH-dependent Cushing's syndrome.

• CRN09682, a nonpeptide drug conjugate, is in Phase 1/2 for neuroendocrine tumors and other SST2+ tumors, with promising preclinical data.

Clinical data and patient impact

• PALSONIFY demonstrated rapid, reliable, and consistent biochemical control in both switch and naïve acromegaly patients, with a favorable safety profile and low discontinuation rates.

• Atumelnant showed rapid and sustained reductions in A4, the key biomarker for CAH, and was well tolerated with no serious adverse events.

• Atumelnant also showed profound, rapid, and sustained reduction of excess cortisol in ACTH-dependent Cushing's syndrome in early studies.